ARTICLE | Product Development

GSK to provide adjuvant to boost effectiveness, stretch supplies of 2019-nCoV vaccines

February 3, 2020 4:41 AM UTC
Updated on Mar 26, 2020 at 1:06 AM UTC

GlaxoSmithKline will provide its AS03 adjuvant technology to enhance 2019-nCoV vaccines that are being funded by the Coalition for Epidemic Preparedness Innovations, GSK and CEPI announced Sunday.

AS03 has been used in GSK’s H1N1 and H5N1 pandemic influenza vaccines...

Access The Full Article